An observational, safety follow-up extension to studies 2203 and 2203E1 to assess the safety of AAE581 in postmenopausal women with osteopenia/osteoporosis

Trial Profile

An observational, safety follow-up extension to studies 2203 and 2203E1 to assess the safety of AAE581 in postmenopausal women with osteopenia/osteoporosis

Completed
Phase of Trial: Phase II

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Balicatib (Primary)
  • Indications Postmenopausal osteoporosis
  • Focus Biomarker; Pharmacodynamics
  • Sponsors Novartis
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 20 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top